Interleukin-17 in transverse myelitis and multiple sclerosis

Jerome J. Graber, S. Rameeza Allie, Katherine M. Mullen, Melina V. Jones, Tongguang Wang, Chitra Krishnan, Adam I. Kaplin, Avi Nath, Douglas A. Kerr, Peter A. Calabresi

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.

Original languageEnglish (US)
Pages (from-to)124-132
Number of pages9
JournalJournal of Neuroimmunology
Volume196
Issue number1-2
DOIs
StatePublished - May 30 2008
Externally publishedYes

Fingerprint

Transverse Myelitis
Interleukin-17
Multiple Sclerosis
Interleukin-6
Nervous System Diseases
Astrocytes
Blood Cells
Cytokines
Interleukin-1

Keywords

  • Astrocytes
  • Interleukin 17
  • Interleukin 6
  • Multiple sclerosis
  • T cells
  • Transverse myelitis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Graber, J. J., Allie, S. R., Mullen, K. M., Jones, M. V., Wang, T., Krishnan, C., ... Calabresi, P. A. (2008). Interleukin-17 in transverse myelitis and multiple sclerosis. Journal of Neuroimmunology, 196(1-2), 124-132. https://doi.org/10.1016/j.jneuroim.2008.02.008

Interleukin-17 in transverse myelitis and multiple sclerosis. / Graber, Jerome J.; Allie, S. Rameeza; Mullen, Katherine M.; Jones, Melina V.; Wang, Tongguang; Krishnan, Chitra; Kaplin, Adam I.; Nath, Avi; Kerr, Douglas A.; Calabresi, Peter A.

In: Journal of Neuroimmunology, Vol. 196, No. 1-2, 30.05.2008, p. 124-132.

Research output: Contribution to journalArticle

Graber, JJ, Allie, SR, Mullen, KM, Jones, MV, Wang, T, Krishnan, C, Kaplin, AI, Nath, A, Kerr, DA & Calabresi, PA 2008, 'Interleukin-17 in transverse myelitis and multiple sclerosis', Journal of Neuroimmunology, vol. 196, no. 1-2, pp. 124-132. https://doi.org/10.1016/j.jneuroim.2008.02.008
Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C et al. Interleukin-17 in transverse myelitis and multiple sclerosis. Journal of Neuroimmunology. 2008 May 30;196(1-2):124-132. https://doi.org/10.1016/j.jneuroim.2008.02.008
Graber, Jerome J. ; Allie, S. Rameeza ; Mullen, Katherine M. ; Jones, Melina V. ; Wang, Tongguang ; Krishnan, Chitra ; Kaplin, Adam I. ; Nath, Avi ; Kerr, Douglas A. ; Calabresi, Peter A. / Interleukin-17 in transverse myelitis and multiple sclerosis. In: Journal of Neuroimmunology. 2008 ; Vol. 196, No. 1-2. pp. 124-132.
@article{7b62e00b61024796b07b39b1b75df1cd,
title = "Interleukin-17 in transverse myelitis and multiple sclerosis",
abstract = "CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.",
keywords = "Astrocytes, Interleukin 17, Interleukin 6, Multiple sclerosis, T cells, Transverse myelitis",
author = "Graber, {Jerome J.} and Allie, {S. Rameeza} and Mullen, {Katherine M.} and Jones, {Melina V.} and Tongguang Wang and Chitra Krishnan and Kaplin, {Adam I.} and Avi Nath and Kerr, {Douglas A.} and Calabresi, {Peter A.}",
year = "2008",
month = "5",
day = "30",
doi = "10.1016/j.jneuroim.2008.02.008",
language = "English (US)",
volume = "196",
pages = "124--132",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Interleukin-17 in transverse myelitis and multiple sclerosis

AU - Graber, Jerome J.

AU - Allie, S. Rameeza

AU - Mullen, Katherine M.

AU - Jones, Melina V.

AU - Wang, Tongguang

AU - Krishnan, Chitra

AU - Kaplin, Adam I.

AU - Nath, Avi

AU - Kerr, Douglas A.

AU - Calabresi, Peter A.

PY - 2008/5/30

Y1 - 2008/5/30

N2 - CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.

AB - CSF IL-6 is elevated in transverse myelitis (TM) and predicts disability. Since IL-17 regulates cytokines (TNFα, IL-1β and IL-6) known to stimulate IL-6 production by astrocytes, we sought to determine whether IL-17 was increased in TM and MS compared to healthy controls (HC) and other neurologic diseases (OND). IL-17 and IL-6 levels were measured in stimulated peripheral blood mononuclear cell (PBMC) supernatants from HC, MS, TM and OND. IL-17 was increased in TM compared to HC, MS, and OND (mean pg/ml ± standard error; HC: 36.1 ± 11.7, MS: 89.4 ± 23.3, TM: 302.6 ± 152.5, OND: 41.2 ± 13.0, p = 0.01). IL-6 was increased in TM relative to MS and HC (HC: 2624 pg/ml ± 641, MS: 6129 ± 982, TM: 12,536 ± 2657, OND: 6920 ± 1801, p < 0.002). MS patients with early disease (< 2 years) also had increased levels of IL-17 (p < 0.04) and IL-6 (p < 0.05). Cytokine neutralization experiments demonstrated that IL-6 was the main inducer of astrocyte IL-6 production. We conclude that IL-17 and IL-6 production from PBMC in TM and early MS are increased and induce astrocyte IL-6 production through IL-6.

KW - Astrocytes

KW - Interleukin 17

KW - Interleukin 6

KW - Multiple sclerosis

KW - T cells

KW - Transverse myelitis

UR - http://www.scopus.com/inward/record.url?scp=44349141220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349141220&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2008.02.008

DO - 10.1016/j.jneuroim.2008.02.008

M3 - Article

VL - 196

SP - 124

EP - 132

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -